O
Selected References
- PDF / 282,322 Bytes
- 13 Pages / 595.28 x 790.87 pts Page_size
- 1 Downloads / 253 Views
L.K. Golightly et al. (eds.), Renal Pharmacotherapy, DOI 10.1007/978-1-4614-5800-5_14, © Springer Science+Business Media New York 2013
497
Dosage Adjustment of Medications Eliminated by the Kidneys
Ofloxacin - Selected References Bagon JA. Neuropsychiatric complications following quinolone overdose in renal failure [letter]. Nephrol Dial Transplant. 1999;14:1337. De Bleecker JL, Vervaet VL, De Sarro A. Reversible orofacial dyskinesia after ofloxacin treatment. Mov Disord. 2004;19:731–2. Dörfler A, Schulz W, Burkhardt F, Zichner M. Pharmacokinetics of ofloxacin in patients on haemodialysis treatment. Drugs. 1987;34(Suppl 1):62–70. Fillastre JP, Leroy A, Humbert G. Ofloxacin pharmacokinetics in renal failure. Antimicrob Agents Chemother. 1987;31:156–60. Flor S, Guay D, Opsahl J, Tack K, Matzke G. Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment. Int J Clin Pharmacol Res. 1991;11:115–21. Fuhrmann V, Schenk P, Mittermayer C, El Menyawi I, Ratheiser K, Thalhammer F. Single-dose pharmacokinetics of ofloxacin during continuous venovenous hemofiltration in critical care patients. Am J Kidney Dis. 2003;42:310–4. Gilbert DN, Moellering RC Jr, Eliopoulos GM, Chambers HF, Saag MS. The sanford guide to antimicrobial therapy. 41st ed. Sperryville: Antimicrobial Therapy Inc; 2011. Gusek A, Bren AF, Lindic J, Hergouth V, Mlinsek D. Is monotherapy with cefazolin or ofloxacin an adequate treatment for peritonitis in CAPD patients? Perit Dial Int. 1994;10:144–6. Höffler D, Koeppe P. Pharmacokinetics of ofloxacin in healthy patients and patients with impaired renal function. Drugs. 1987;34(Suppl 1):51–5. Kampf D, Borner K, Pustelnik A. Pharmacokinetics of ofloxacin and adequacy of maintenance dose for patients on haemodialysis. J Antimicrob Chemother. 1990;26(Suppl D):61–8. Kampf D, Borner K, Pustelnik A. Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients. Eur J Clin Pharmacol. 1992;42:95–9. Lameire N, Rosenkranz B, Malerczyk V, Lehr K-H, Veys N, Ringoir S. Ofloxacin pharmacokinetics in chronic renal failure and dialysis. Clin Pharmacokinet. 1991;21:357–71. Lamp KC, Bailey EM, Rybak MJ. Ofloxacin clinical pharmacokinetics. Clin Pharmacokinet. 1992;22:32–46. McMullin CM, Brown NM, Brown IM, et al. The pharmacokinetics of once-daily oral 400 mg ofloxacin in patients with peritonitis complicating continuous ambulatory peritoneal dialysis. J Antimicrob Chemother. 1997;39:829–31. Molinaro M, Villani P, Regazzi MB, Rondanelli R, Doveri G. Pharmacokinetics of ofloxacin in elderly and in healthy young subjects. Eur J Clin Pharmacol. 1992;43:105–7. Naber KG, Adam D, Kees F. In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients. Drugs. 1987;34(Suppl 1):44–50. Ofloxacin tablet film coated [package insert]. Sellersville: Teva Pharmaceuticals USA; 2011. Passlick J, Wonner R, Keller E, Essers L, Grabensee B. Single and multiple-dose kinetics of ofloxacin in patients on continuous
Data Loading...
